{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:21:36Z","timestamp":1787930496122,"version":"build-2784847793"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D15CA-026"],"award-info":[{"award-number":["D15CA-026"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008747","name":"Center for Clinical and Translational Science, Ohio State University","doi-asserted-by":"publisher","award":["UL1TR002733"],"award-info":[{"award-number":["UL1TR002733"]}],"id":[{"id":"10.13039\/100008747","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OSU College of Veterinary Medicine Canine Grant","award":["2016-06"],"award-info":[{"award-number":["2016-06"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Non-Hodgkin lymphoma (NHL) is a heterogeneous group of blood cancers arising in lymphoid tissues that commonly effects both humans and dogs. Protein arginine methyltransferase 5 (PRMT5), an enzyme that catalyzes the symmetric di-methylation of arginine residues, is frequently overexpressed and dysregulated in both human solid and hematologic malignancies. In human lymphoma, PRMT5 is a known driver of malignant transformation and oncogenesis, however, the expression and role of PRMT5 in canine lymphoma has not been explored. To explore canine lymphoma as a useful comparison to human lymphoma while validating PRMT5 as a rational therapeutic target in both, we characterized expression patterns of PRMT5 in canine lymphoma tissue microarrays, primary lymphoid biopsies, and canine lymphoma-derived cell lines. The inhibition of PRMT5 led to growth suppression and induction of apoptosis, while selectively decreasing global marks of symmetric dimethylarginine (SDMA) and histone H4 arginine 3 symmetric dimethylation. We performed ATAC-sequencing and gene expression microarrays with pathway enrichment analysis to characterize genome-wide changes in chromatin accessibility and whole-transcriptome changes in canine lymphoma cells lines upon PRMT5 inhibition. This work validates PRMT5 as a promising therapeutic target for canine lymphoma and supports the continued use of the spontaneously occurring canine lymphoma model for the preclinical development of PRMT5 inhibitors for the treatment of human NHL.<\/jats:p>","DOI":"10.1371\/journal.pone.0250839","type":"journal-article","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T17:37:01Z","timestamp":1621013821000},"page":"e0250839","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7366-9184","authenticated-orcid":true,"given":"Shelby L.","family":"Sloan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Renaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay E.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-3130","authenticated-orcid":true,"given":"Konstantin","family":"Shilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schlotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G.","family":"Klamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse S.","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice G.","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Vaddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Scherle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Kisseberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"issue":"1","key":"pone.0250839.ref001","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/0300985810379428","article-title":"Classification of canine malignant lymphomas according to the World Health Organization criteria","volume":"48","author":"VE Valli","year":"2011","journal-title":"Vet Pathol"},{"issue":"1","key":"pone.0250839.ref002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1476-5829.2009.00201.x","article-title":"Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO","volume":"8","author":"E Vezzali","year":"2010","journal-title":"Vet Comp Oncol"},{"issue":"4","key":"pone.0250839.ref003","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/0300985812465325","article-title":"Molecular profiling reveals prognostically significant subtypes of canine lymphoma","volume":"50","author":"AM Frantz","year":"2013","journal-title":"Vet Pathol"},{"issue":"3","key":"pone.0250839.ref004","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0300985810363902","article-title":"A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology","volume":"47","author":"F Ponce","year":"2010","journal-title":"Vet Pathol"},{"issue":"11","key":"pone.0250839.ref005","first-page":"3909","article-title":"The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","year":"1997","journal-title":"Blood"},{"issue":"3\u20134","key":"pone.0250839.ref006","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"D Ito","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"issue":"2","key":"pone.0250839.ref007","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/gcc.22126","article-title":"Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma","volume":"53","author":"E Bohers","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"97","key":"pone.0250839.ref008","first-page":"51","article-title":"Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy","volume":"18","author":"F Jardin","year":"2014","journal-title":"Discov Med"},{"issue":"6","key":"pone.0250839.ref009","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1939-1676.2007.tb01959.x","article-title":"Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma","volume":"21","author":"K Hosoya","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"3","key":"pone.0250839.ref010","first-page":"196","article-title":"Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases","volume":"8","author":"K Sorenmo","year":"2010","journal-title":"Vet Comp Oncol"},{"issue":"9378","key":"pone.0250839.ref011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(03)13868-8","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"LS Evans","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"pone.0250839.ref012","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"LR Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pone.0250839.ref013","first-page":"483","article-title":"Current approaches to the management of non-Hodgkin\u2019s lymphoma","volume":"25","author":"JM Vose","year":"1998","journal-title":"Semin Oncol"},{"issue":"26","key":"pone.0250839.ref014","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: diffuse large B-cell lymphoma","volume":"23","author":"B Coiffier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"pone.0250839.ref015","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"N Stopa","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"94","key":"pone.0250839.ref016","first-page":"36705","article-title":"dysregulation in cancer","volume":"9","author":"H Shailesh","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0250839.ref017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41467-018-07884-6","article-title":"PRMT5 is essential for B cell development and germinal center dynamics","volume":"10","author":"LC Litzler","year":"2019","journal-title":"Nat Commun"},{"issue":"24","key":"pone.0250839.ref018","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1101\/gad.606110","article-title":"Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency","volume":"24","author":"WW Tee","year":"2010","journal-title":"Genes Dev"},{"issue":"7","key":"pone.0250839.ref019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/embo-reports\/kvf136","article-title":"Negative regulation of transcription by the type II arginine methyltransferase PRMT5","volume":"3","author":"E Fabbrizio","year":"2002","journal-title":"EMBO Rep"},{"issue":"21","key":"pone.0250839.ref020","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1128\/MCB.24.21.9630-9645.2004","article-title":"Human SWI\/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes","volume":"24","author":"S Pal","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"4","key":"pone.0250839.ref021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/leu.2015.308","article-title":"The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation","volume":"30","author":"SS Tarighat","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"pone.0250839.ref022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nsmb.2209","article-title":"Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance","volume":"19","author":"V Migliori","year":"2012","journal-title":"Nat Struct Mol Biol"},{"issue":"33","key":"pone.0250839.ref023","doi-asserted-by":"crossref","first-page":"13516","DOI":"10.1073\/pnas.1311784110","article-title":"PRMT5 dimethylates R30 of the p65 subunit to activate NF-\u03baB","volume":"110","author":"H Wei","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"pone.0250839.ref024","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/nar\/gkq1264","article-title":"A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage","volume":"39","author":"W He","year":"2011","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"pone.0250839.ref025","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2018-02-831438","article-title":"PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival","volume":"132","author":"X Lu","year":"2018","journal-title":"Blood"},{"issue":"15","key":"pone.0250839.ref026","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","article-title":"Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma","volume":"26","author":"S Pal","year":"2007","journal-title":"EMBO J"},{"issue":"3","key":"pone.0250839.ref027","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","article-title":"PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers","volume":"5","author":"Y Li","year":"2015","journal-title":"Cancer Discov"},{"issue":"6","key":"pone.0250839.ref028","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1158\/0008-5472.CAN-13-0884","article-title":"Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma","volume":"74","author":"F Yan","year":"2014","journal-title":"Cancer Res"},{"key":"pone.0250839.ref029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1746-1596-8-201","article-title":"Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors","volume":"8","author":"K Shilo","year":"2013","journal-title":"Diagn Pathol"},{"issue":"9","key":"pone.0250839.ref030","doi-asserted-by":"crossref","first-page":"e74710","DOI":"10.1371\/journal.pone.0074710","article-title":"PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.)","volume":"8","author":"C Nicholas","year":"2013","journal-title":"PLoS One"},{"issue":"26","key":"pone.0250839.ref031","doi-asserted-by":"crossref","first-page":"22799","DOI":"10.18632\/oncotarget.4332","article-title":"Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3","volume":"6","author":"B Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0250839.ref032","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12967-015-0721-8","article-title":"Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin","volume":"13","author":"B Zhang","year":"2015","journal-title":"J Transl Med"},{"issue":"16","key":"pone.0250839.ref033","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"L Alinari","year":"2015","journal-title":"Blood"},{"issue":"1","key":"pone.0250839.ref034","doi-asserted-by":"crossref","DOI":"10.3390\/v8010007","article-title":"PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival","volume":"8","author":"AR Panfil","year":"2015","journal-title":"Viruses"},{"issue":"7558","key":"pone.0250839.ref035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature14351","article-title":"MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis","volume":"523","author":"CM Koh","year":"2015","journal-title":"Nature"},{"issue":"12","key":"pone.0250839.ref036","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1038\/s41375-019-0489-6","article-title":"PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K\/AKT in lymphoma cells","volume":"33","author":"F Zhu","year":"2019","journal-title":"Leukemia"},{"issue":"49","key":"pone.0250839.ref037","doi-asserted-by":"crossref","first-page":"35534","DOI":"10.1074\/jbc.M113.510669","article-title":"Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing","volume":"288","author":"J Chung","year":"2013","journal-title":"J Biol Chem"},{"key":"pone.0250839.ref038","article-title":"PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN","author":"F Pastore","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"pone.0250839.ref039","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"E Chan-Penebre","year":"2015","journal-title":"Nat Chem Biol"},{"issue":"8","key":"pone.0250839.ref040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131099","article-title":"PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease","volume":"5","author":"KJ Snyder","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"pone.0250839.ref041","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/acsmedchemlett.8b00014","article-title":"LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity","volume":"9","author":"ZQ Bonday","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"23","key":"pone.0250839.ref042","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1158\/1078-0432.CCR-18-1498","article-title":"NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma","volume":"24","author":"JH Burton","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0250839.ref043","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4161\/auto.29165","article-title":"Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma","volume":"10","author":"RA Barnard","year":"2014","journal-title":"Autophagy"},{"issue":"2","key":"pone.0250839.ref044","doi-asserted-by":"crossref","first-page":"e87585","DOI":"10.1371\/journal.pone.0087585","article-title":"Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study","volume":"9","author":"CA London","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"pone.0250839.ref045","doi-asserted-by":"crossref","first-page":"e0195357","DOI":"10.1371\/journal.pone.0195357","article-title":"Phase I\/II evaluation of RV1001, a novel PI3K\u03b4 inhibitor, in spontaneous canine lymphoma","volume":"13","author":"HL Gardner","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"pone.0250839.ref046","doi-asserted-by":"crossref","first-page":"e0159607","DOI":"10.1371\/journal.pone.0159607","article-title":"Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma","volume":"11","author":"BK Harrington","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0250839.ref047","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12917-018-1587-9","article-title":"Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma","volume":"14","author":"AR Sadowski","year":"2018","journal-title":"BMC Vet Res"},{"issue":"5","key":"pone.0250839.ref048","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cvsm.2019.04.005","article-title":"Targeted Therapies in Veterinary Oncology","volume":"49","author":"P Londhe","year":"2019","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"12","key":"pone.0250839.ref049","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"JD Buenrostro","year":"2013","journal-title":"Nat Methods"},{"key":"pone.0250839.ref050","doi-asserted-by":"crossref","first-page":"15494","DOI":"10.1038\/srep15494","article-title":"Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells","volume":"5","author":"MP Mongiardi","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0250839.ref051","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.molonc.2014.10.015","article-title":"Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells","volume":"9","author":"JH Park","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"pone.0250839.ref052","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-014-1419-0","article-title":"Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro","volume":"118","author":"X Han","year":"2014","journal-title":"J Neurooncol"},{"issue":"8","key":"pone.0250839.ref053","doi-asserted-by":"crossref","first-page":"e44033","DOI":"10.1371\/journal.pone.0044033","article-title":"Protein arginine methyltransferase 5 functions in opposite ways in the cytoplasm and nucleus of prostate cancer cells","volume":"7","author":"Z Gu","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"pone.0250839.ref054","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ijc.31909","article-title":"LKB1 regulates PRMT5 activity in breast cancer","volume":"144","author":"H Lattouf","year":"2019","journal-title":"Int J Cancer"},{"issue":"34","key":"pone.0250839.ref055","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.18632\/oncotarget.26883","article-title":"PRMT5 prognostic value in cancer","volume":"10","author":"H Lattouf","year":"2019","journal-title":"Oncotarget"},{"key":"pone.0250839.ref056","article-title":"Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma","author":"V Karkhanis","year":"2019","journal-title":"J Biol Chem"},{"issue":"10","key":"pone.0250839.ref057","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nmeth.4396","article-title":"An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues","volume":"14","author":"MR Corces","year":"2017","journal-title":"Nat Methods"},{"issue":"1","key":"pone.0250839.ref058","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41598-018-36927-7","article-title":"High Quality ATAC-Seq Data Recovered from Cryopreserved Breast Cell Lines and Tissue","volume":"9","author":"S Fujiwara","year":"2019","journal-title":"Sci Rep"},{"issue":"19","key":"pone.0250839.ref059","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1074\/jbc.RA119.007640","article-title":"Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT\/beta-catenin and AKT\/GSK3beta proliferative signaling","volume":"294","author":"J Chung","year":"2019","journal-title":"J Biol Chem"},{"issue":"12","key":"pone.0250839.ref060","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"V Karkhanis","year":"2011","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"pone.0250839.ref061","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00205629","article-title":"Canine lymphoma-associated antigens defined by murine monoclonal antibodies","volume":"24","author":"Z Steplewski","year":"1987","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"pone.0250839.ref062","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1476-5829.2011.00299.x","article-title":"Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines","volume":"11","author":"EL Seiser","year":"2013","journal-title":"Vet Comp Oncol"},{"issue":"7","key":"pone.0250839.ref063","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","article-title":"Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma","volume":"34","author":"BC R\u00fctgen","year":"2010","journal-title":"Leuk Res"},{"issue":"12","key":"pone.0250839.ref064","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.leukres.2007.04.003","article-title":"A novel canine lymphoma cell line: a translational and comparative model for lymphoma research","volume":"31","author":"WC Kisseberth","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"pone.0250839.ref065","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1038\/s41598-018-23207-7","article-title":"Comparative High-Resolution Transcriptome Sequencing of Lymphoma Cell Lines and de novo Lymphomas Reveals Cell-Line-Specific Pathway Dysregulation","volume":"8","author":"L Taher","year":"2018","journal-title":"Sci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T17:37:52Z","timestamp":1621013872000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250839"}},"subtitle":[],"editor":[{"given":"Douglas H.","family":"Thamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0250839","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]}}}